Ghrelin receptor agonists - Pipeline Insight, 2022
Description
“Ghrelin Receptor Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ghrelin Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Ghrelin Receptor Agonist Understanding
Ghrelin Receptor Agonist: Overview
Ghrelin is a hormone produced by specific cells in the stomach. It exerts its action by binding to receptors in the hypothalamus involved in the regulation of food intake. Ghrelin causes an increase in the pituitary secretion of growth hormone (GH). Drugs that bind and activate the ghrelin receptor have been explored for their effect on appetite, weight gain, frailty, cachexia, inflammation and gut motility. Ghrelin exerts its effects through a specific G‐protein‐coupled receptor called the growth hormone secretagogue receptor 1a (GHS‐R1a). Another GHS‐R cDNA is produced by alternative splicing which produces a COOH‐terminal truncated form (GHS‐R1b) that is pharmacologically inactive. The GHS‐R1a is expressed in several areas of the hypothalamus associated with feeding behaviour, including the arcuate and ventromedial nuclei. GHS‐R1a is also found in the pituitary gland, and other organs such as bone, heart, lung, liver, kidney, pancreas and immune cells.
Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Ghrelin Receptor Agonist R&D. The therapies under development are focused on novel approaches for Ghrelin Receptor Agonist.
Ghrelin Receptor Agonist Emerging Drugs Chapters
This segment of the Ghrelin Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ghrelin Receptor Agonist Emerging Drugs
• Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects. everal randomized, double-blind, clinical trials in cancer patients have shown that anamorelin HCL is safe, efficacious and increases lean body mass, bodyweight, and appetite. Investigators propose to test anamorelin HCL administered with chemotherapy in the first-line treatment of locally advanced unresectable and metastatic pancreatic cancer. Its Phase II trial is expected to start in August 2021.
Further product details are provided in the report……..
Ghrelin Receptor Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Ghrelin Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Ghrelin Receptor Agonist
There are approx. 5+ key companies which are developing the Ghrelin Receptor Agonist. The companies which have their Ghrelin Receptor Agonist drug candidates in the most advanced stage, i.e. Phase II include, Helsinn Therapeutics/Ono Pharmaceutical.
• Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Ghrelin Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ghrelin Receptor Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ghrelin Receptor Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ghrelin Receptor Agonist drugs.
Ghrelin Receptor Agonist Report Insights
• Ghrelin Receptor Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Ghrelin Receptor Agonist Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
• How many companies are developing Ghrelin Receptor Agonist drugs?
• How many Ghrelin Receptor Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Ghrelin Receptor Agonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ghrelin Receptor Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ghrelin Receptor Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Helsinn Therapeutics/Ono Pharmaceutical
• AEterna Zentaris
Key Products
• Anamorelin HCl
• Macimorelin
Geography Covered
• Global coverage
Ghrelin Receptor Agonist Understanding
Ghrelin Receptor Agonist: Overview
Ghrelin is a hormone produced by specific cells in the stomach. It exerts its action by binding to receptors in the hypothalamus involved in the regulation of food intake. Ghrelin causes an increase in the pituitary secretion of growth hormone (GH). Drugs that bind and activate the ghrelin receptor have been explored for their effect on appetite, weight gain, frailty, cachexia, inflammation and gut motility. Ghrelin exerts its effects through a specific G‐protein‐coupled receptor called the growth hormone secretagogue receptor 1a (GHS‐R1a). Another GHS‐R cDNA is produced by alternative splicing which produces a COOH‐terminal truncated form (GHS‐R1b) that is pharmacologically inactive. The GHS‐R1a is expressed in several areas of the hypothalamus associated with feeding behaviour, including the arcuate and ventromedial nuclei. GHS‐R1a is also found in the pituitary gland, and other organs such as bone, heart, lung, liver, kidney, pancreas and immune cells.
Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Ghrelin Receptor Agonist R&D. The therapies under development are focused on novel approaches for Ghrelin Receptor Agonist.
Ghrelin Receptor Agonist Emerging Drugs Chapters
This segment of the Ghrelin Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ghrelin Receptor Agonist Emerging Drugs
• Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects. everal randomized, double-blind, clinical trials in cancer patients have shown that anamorelin HCL is safe, efficacious and increases lean body mass, bodyweight, and appetite. Investigators propose to test anamorelin HCL administered with chemotherapy in the first-line treatment of locally advanced unresectable and metastatic pancreatic cancer. Its Phase II trial is expected to start in August 2021.
Further product details are provided in the report……..
Ghrelin Receptor Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Ghrelin Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Ghrelin Receptor Agonist
There are approx. 5+ key companies which are developing the Ghrelin Receptor Agonist. The companies which have their Ghrelin Receptor Agonist drug candidates in the most advanced stage, i.e. Phase II include, Helsinn Therapeutics/Ono Pharmaceutical.
• Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Ghrelin Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ghrelin Receptor Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ghrelin Receptor Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ghrelin Receptor Agonist drugs.
Ghrelin Receptor Agonist Report Insights
• Ghrelin Receptor Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Ghrelin Receptor Agonist Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
• How many companies are developing Ghrelin Receptor Agonist drugs?
• How many Ghrelin Receptor Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Ghrelin Receptor Agonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ghrelin Receptor Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ghrelin Receptor Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Helsinn Therapeutics/Ono Pharmaceutical
• AEterna Zentaris
Key Products
• Anamorelin HCl
• Macimorelin
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Ghrelin Receptor Agonist: Overview
- • Structure
- • Mechanism of Action
- Pipeline Therapeutics
- • Comparative Analysis
- Therapeutic Assessment
- • Assessment by Product Type
- • Assessment by Stage and Product Type
- • Assessment by Route of Administration
- • Assessment by Stage and Route of Administration
- • Assessment by Molecule Type
- • Assessment by Stage and Molecule Type
- Ghrelin Receptor Agonist – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- • Ghrelin Receptor Agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Ghrelin Receptor Agonist Collaboration Deals
- • Company-Company Collaborations (Licensing / Partnering) Analysis
- • Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- • Comparative Analysis
- Drug Name: Company Name
- • Product Description
- • Research and Development
- • Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- • Comparative Analysis
- Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
- • Product Description
- • Research and Development
- • Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- • Comparative Analysis
- Drug Name: Company Name
- • Product Description
- • Research and Development
- • Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- • Comparative Analysis
- Macimorelin: AEterna Zentaris
- • Product Description
- • Research and Development
- • Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- • Comparative Analysis
- Ghrelin Receptor Agonist Key Companies
- Ghrelin Receptor Agonist Key Products
- Ghrelin Receptor Agonist- Unmet Needs
- Ghrelin Receptor Agonist- Market Drivers and Barriers
- Ghrelin Receptor Agonist- Future Perspectives and Conclusion
- Ghrelin Receptor Agonist Analyst Views
- Ghrelin Receptor Agonist Key Companies
- Appendix
- Table 1 Total Products for Ghrelin Receptor Agonist
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products
- Figure 1 Total Products for Ghrelin Receptor Agonist
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
